New Cellular Therapy Gives Hope for Schizophrenia

By: Dylan Sikes – AllPennyStocks.com News

Thursday, June 10, 2021

Therapy cells, or T cells, help control the immune system and T regulatory cells help stop autoimmune responses once the threat has been eliminated. Can they also help neurological illnesses such as schizophrenia? Campbell Neurosciences is working to find ways to help patients of this disease.

Campbell Neurosciences is a subsidiary of Therapeutic Solutions International (OTCPK:TSOI). Today the firm announced that recent data showed the effect of certain cells in an animal model of schizophrenia resulted in suppression of multiple neurological manifestations of the condition. There was a clear association between increased numbers of T regulatory cells and therapeutic activity.

According to Dr. James Veltmeyer, Chief Medical Officer of the Company, “The interplay between the brain and the immune system is the foundation of Campbell Neurosciences, and I am very excited to lead the translation of this very relevant animal study into human clinical trials.”

Campbell Neurosciences is focused on ending suicide using immunology and regenerative psychiatry. Therapeutic Solutions has 13 patent applications filed covering diagnostics and therapeutic solutions. Shares of Therapeutic Solutions were trading up almost 2% in mid-afternoon trade.

Copyright © 2021 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.